Jeff Conroy, CEO of Embody. Jeff is on a mission to create a new standard of care in the treatment of tendon and ligament injuries.
Embody is a medical device company focused on the sports medicine market and specifically collagen-based surgical implants for the treatment of tendon and ligament injuries such as Achilles, Rotator Cuff and ACL. Embody has been funded by the Defense Advanced Research Projects Agency (DARPA) and the Department of Defense (US Army and US Air Force) with over $21 million in non-dilutive funding since 2015. Embody has previously raised $9.3 million in Series A financing in early 2020. Embody will launch our first product, Tapestry, following FDA 510(k) clearance in October 2020 and begin patient cases. We will launch four products over the next three years and build a $50 million+ revenue stream by 2025. As we become a commercial company and a growth-stage investment, we are seeking $15 to $20 million in Series B funding to accelerate commercial adoption and product development.